Carotid body function in heart failure

Harold D Schultz1, Yu Long Li

  • 1Department of Cellular and Integrative Physiology, University of Nebraska College of Medicine, 985850 Nebraska Medical Center, Omaha, NE 68198-5850, USA. hschultz@unmc.edu

Insights

The carotid body (CB) chemoreflex is enhanced in chronic heart failure (CHF), increasing sympathetic nerve activity (SNA). This involves altered signaling in the CB and central nervous system (CNS), with angiotensin II and nitric oxide playing key roles.

Area of Science:

  • Cardiovascular Physiology
  • Neuroscience
  • Renal Physiology

Background:

  • Chronic heart failure (CHF) is associated with elevated sympathetic nerve activity (SNA).
  • The carotid body (CB) chemoreflex is implicated in regulating SNA.
  • Understanding the CB's role in CHF is crucial for therapeutic development.

Purpose of the Study:

  • To review the functional characteristics of the CB chemoreflex in controlling SNA in CHF.
  • To elucidate the mechanisms underlying enhanced CB chemoreflex activity in CHF.
  • To identify the roles of specific signaling pathways in the CB and CNS.

Main Methods:

  • Review of existing literature on CB chemoreflex in CHF.
  • Analysis of evidence from both human patients and animal models of CHF.
  • Examination of cellular and molecular mechanisms within the CB and CNS.

Main Results:

  • The CB chemoreflex is enhanced in CHF, contributing to elevated SNA.
  • Altered afferent discharge and ion channel function (K+ currents) in CB glomus cells.
  • Downregulation of nitric oxide synthase (NOS)/NO and upregulation of angiotensin II (Ang II)/AT1R signaling in CB glomus cells.
  • Central nervous system (CNS) interactions, including altered baroreceptor input and central Ang II, further increase sympathetic drive.
  • Impaired NO function in the hypothalamus contributes to enhanced SNA.

Conclusions:

  • The enhanced CB chemoreflex in CHF is a multi-faceted adaptation.
  • Both the CB and CNS exhibit altered signaling, involving Ang II and NO.
  • These complementary mechanisms aim to increase CB chemoreflex function in CHF.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...